Compare FKWL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FKWL | GANX |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 159.2M |
| IPO Year | 1996 | 2021 |
| Metric | FKWL | GANX |
|---|---|---|
| Price | $4.26 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | 12.8K | ★ 2.2M |
| Earning Date | 02-13-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,508,949.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.05 | N/A |
| 52 Week Low | $3.67 | $1.41 |
| 52 Week High | $7.45 | $4.34 |
| Indicator | FKWL | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 41.22 | 48.63 |
| Support Level | $4.12 | $2.90 |
| Resistance Level | $4.42 | $3.45 |
| Average True Range (ATR) | 0.16 | 0.46 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 28.17 | 45.23 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.